Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334

Trial Profile

An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 02 May 2019 According to an Amgen media release, data from this trial will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia.
    • 01 Jul 2018 Interim results (n=383) presented at the 60th Annual Scientific Meeting of the American Headache Society.
    • 29 Jun 2018 Results presented in an Amgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top